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Summary
Background An increase in worldwide HPV vaccination could be facilitated if fewer than three doses of vaccine are as 
eﬀ ective as three doses. We originally aimed to compare the immunogenicity and frequency of persistent infection 
and cervical precancerous lesions caused by vaccine-targeted HPV after vaccination with two doses of quadrivalent 
vaccine on days 1 and 180 or later, with three doses on days 1, 60, and 180 or later, in a cluster-randomised trial. 
Suspension of the recruitment and vaccination due to events unrelated to our study meant that some enrolled girls 
could not be vaccinated and some vaccinated girls received fewer than the planned number of vaccinations by default. 
As a result, we re-analysed our data as an observational cohort study. 
Methods Our study was designed to be done in nine locations (188 clusters) in India. Participants were unmarried 
girls aged 10–18 years vaccinated in four cohorts: girls who received three doses of vaccine on days 1, 60, and 180 or 
later, two doses on days 1 and 180 or later, two doses on days 1 and 60 by default, and one dose by default. The primary 
outcomes were immunogenicity in terms of L1 genotype-speciﬁ c binding antibody titres, neutralising antibody titres, 
and antibody avidity after vaccination for the vaccine-targeted HPV types 16, 18, 6, and 11 and incident and persistent 
infections with these HPVs. Analysis was per actual number of vaccine doses received. This study is registered with 
ISRCTN, number ISRCTN98283094; and with ClinicalTrials.gov, number NCT00923702.
Findings Vaccination of eligible girls was initiated on Sept 1, 2009, and continued until April 8, 2010. Of 21 258 eligible 
girls identiﬁ ed at 188 clusters, 17 729 girls were recruited from 178 clusters before suspension. 4348 (25%) girls received 
three doses, 4979 (28%) received two doses on days 1 and 180 or later, 3452 (19%) received two doses at days 1 and 60, 
and 4950 (28%) received one dose. Immune response in the two-dose HPV vaccine group was non-inferior to the three-
dose group (median ﬂ uorescence intensity ratio for HPV 16 1·12 [95% CI 1·02–1·23] and for HPV 18 1·04 [0·92–1·19]) 
at 7 months, but was inferior in the two-dose default (0·33 [0·29–0·38] for HPV 16 and 0·51 [0·43–0·59] for HPV 18) 
and one-dose default (0·09 [0·08–0·11] for HPV 16 and 0·12 [0·10–0·14] for HPV 18) groups at 18 months. The geometric 
mean avidity indices after fewer than three doses by design or default were non-inferior to those after three doses of 
vaccine. Fewer than three doses by design and default induced detectable concentrations of neutralising antibodies to all 
four vaccine-targeted HPV types, but at much lower concentration after one dose. Cervical samples from 2649 participants 
were tested and the frequency of incident HPV 16, 18, 6, and 11 infections was similar irrespective of the number of 
vaccine doses received. The testing of at least two samples from 838 participants showed that there was no persistent 
HPV 16 or 18 infections in any study group at a median follow-up of 4·7 years (IQR 4·2–5·1).
Interpretation Despite the limitations imposed by the suspension of the HPV vaccination, our ﬁ ndings lend support 
to the WHO recommendation of two doses, at least 6 months apart, for routine vaccination of young girls. The short-
term protection aﬀ orded by one dose of HPV vaccine against persistent infection with HPV 16, 18, 6, and 11 is similar 
to that aﬀ orded by two or three doses of vaccine and merits further assessment.
Funding Bill & Melinda Gates Foundation.
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Introduction
Persistent infection with a high-risk HPV causes cervical 
cancer, and worldwide 68–82% of cervical cancers are 
attributed to HPV types 16 and 18.1–4 Prophylactic vaccines 
containing recombinant virus-like particles assembled 
from the L1 capsid proteins of HPV 16 and 18 (bivalent 
vaccine) and HPV 6, 11, 16, and 18 (quadrivalent vaccine) 
are used in HPV vaccination programmes. Over 6 months, 
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the eﬃ  cacy of three doses of vaccine (either bivalent or 
quadrivalent) against high-grade cervical intraepithelial 
neoplasia caused by vaccine-targeted HPV was almost 
100% in HPV-naive populations and greater than 55% in 
the intention-to-treat populations.1–3
The administration of three doses of the HPV vaccine, 
or even two doses as recommended by WHO,4,5 is a 
challenge, and if one dose was as eﬀ ective as two or three 
doses then vaccine uptake would increase greatly and 
costs would be reduced. The high immune response in 
pre-adolescent girls given three doses suggests that 
reductions in dose number could prevent cervical 
neoplasia.6,7 Data on immunogenicity, durability of 
antibody response, and frequency of persistent infection 
after one dose will enable the swift introduction of HPV 
vaccination in national immunisation programmes. 
In 2009, we initiated a cluster-randomised trial in India 
to compare the eﬀ ectiveness of two doses versus three 
doses of a quadrivalent vaccine targeting HPV 
types 16, 18, 6, and 11, in preventing cervical neoplasia. 
However, recruitment and vaccination of the girls in the 
trial was suspended midway due to events unrelated to 
our study, which meant that some enrolled girls could not 
be vaccinated and some vaccinated girls received fewer 
than the planned number of vaccinations by default. 
Thus, randomisation was impaired and our study became 
an observational study of four diﬀ erent vaccinated 
cohorts. Here, we describe the immuno genicity and 
infection results after suspension of vaccination.
Methods
Study design and participants
We initiated a multicentre, cluster-randomised trial in 
India on Sept 1, 2009, to ﬁ nd out whether two doses of 
quadrivalent HPV vaccine would be as eﬀ ective in 
inducing non-inferior immune response and in 
preventing persistent vaccine-targeted HPV infection and 
cervical neoplasia as three doses. We recruited unmarried 
girls who were ambulant and in good general health aged 
10–18 years, living in 188 geographical clusters in nine 
locations in India (Osmanabad, Dindigul, Pune, Mumbai, 
Ahmedabad, Delhi, Hyderabad, Gangtok in Sikkim, and 
Aizawl in Mizoram). We chose these regions to represent 
diﬀ erent regions of India. We excluded those in poor 
general health and with severe or debilitating illness. 
The study was reviewed and approved by the ethics 
review committees and institutional review boards of the 
participating centres. The data safety monitoring board 
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Research in context
Evidence before this study
Two doses of the bivalent HPV vaccine given to adolescents 
6 months apart has been shown to induce a non-inferior immune 
response to that of three doses administered on day 1, 1 month, 
and 6 months. One and two doses of the bivalent HPV vaccine 
have been shown to protect against cervical HPV 16 and 18 
infections as eﬀ ectively as three doses in women aged 
15–25 years. In a randomised trial, two doses of quadrivalent HPV 
vaccine given 6 months apart to girls aged 9–13 years resulted in 
a non-inferior immune response at 1 month after the last dose 
compared with three doses given to girls aged 9–13 years and to 
women aged 16–26 years on day 1, 2 months, and 6 months. 
We searched PubMed and MEDLINE for full-length articles 
published between Jan 1, 2008, and June 30, 2015, using the 
keywords “HPV vaccination”, “less than three doses”, “alternate 
doses”, “one dose”, “two doses”, “three doses”, “immunogenicity”, 
“HPV infection”, “cervical intraepithelial neoplasia”, “clinical trials”, 
“randomised trials”, “follow-up studies”; we also searched 
ClinicalTrials.gov for ongoing clinical trials of fewer than three 
doses of the HPV vaccine. We assessed all potentially relevant 
articles and found that neither the immunogenicity after one 
dose of quadrivalent HPV vaccination nor the extent of 
protection against HPV 16 and 18 infections aﬀ orded by fewer 
than three doses of quadrivalent HPV vaccine has been reported.
Added value of the study
Our ﬁ ndings conﬁ rm that two doses of quadrivalent HPV 
vaccine, administered with an interval of 180 days or more, are 
immunologically non-inferior to the three-dose schedule and 
aﬀ ord protection against incident and persistent HPV 16, 18, 6, 
and 11 infection that is similar to that aﬀ orded by three doses. 
We also report the ﬁ rst evidence to our knowledge that one dose 
of quadrivalent HPV vaccine induced detectable titres of HPV 
neutralising antibodies and that lower vaccine-induced antibody 
concentrations after one dose of quadrivalent HPV vaccine 
provide similar protection against vaccine-targeted HPV 
infections compared with the higher antibody concentrations 
induced after two or three doses.
Implications of all the available evidence
Our preliminary results suggest that future trials of HPV 
vaccines should include a single-dose arm. Further long-term 
follow-up of vaccinated women in our study will clarify 
whether protection afforded after one dose of quadrivalent 
HPV vaccine is long-lasting. Our findings after fewer than 
three doses by design or default are consistent with results 
from other studies of fewer than three doses. Administration 
of three doses of HPV vaccine, or two doses as recommended 
by WHO, remains a challenge, and if one dose proves to be as 
efficacious as more doses, vaccine uptake will be improved 
and costs will be reduced. Data on immunogenicity, 
durability of antibody response, and the frequency of 
persistent infection after one dose of vaccine will expedite 
the introduction of HPV vaccination in national 
immunisation programmes. In view of the programmatic 
advantages of vaccinating in one dose, assessment of the 
clinical efficacy of a single dose of vaccine is of great public 
health significance. 
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regularly monitored the safety and outcomes of the study. 
We obtained written informed consent from one of the 
parents or the legal guardian of the participant, with the 
assent of the participant. We obtained a new written 
informed consent from girls who became 18 years old 
during follow-up.
Procedures
The vaccine used was the quadrivalent HPV vaccine 
(Gardasil; Merck Sharp & Dohme, Whitehouse Station, 
NJ, USA). Girls were originally randomly assigned to the 
two-dose group with vaccination on days 1 and 180 (or 
later) or the three-dose group with vaccination on days 1, 
60, and 180 (or later) by the statistician at the International 
Agency for Research on Cancer (IARC). At each project 
site, the identiﬁ ed clusters were randomly assigned into 
two groups using a computer-generated random 
allocation. Also using the computer-generated random 
allocation, the two groups in each study site were then 
randomly assigned to the two-dose group or the three-
dose group. All eligible girls in the randomised clusters 
were enumerated into the study. Vaccinations occurred 
from study start until April 8, 2010, when the Indian 
authorities suspended all further recruitment and 
vaccination of girls in all HPV vaccination trials in India 
because of events unrelated to our study. The suspension 
meant that we had four groups of girls who were 
vaccinated: those on days 1, 60, and 180 or later (original 
three-dose group); those on days 1 and 180 or later 
(original two-dose group); those on days 1 and 60 by 
default (two-dose default group); and those with one dose 
only by default (one-dose default group).
At each study site, dedicated health workers and nurses 
were recruited and trained to identify and interview 
eligible girls for sociodemographic and reproductive 
information, explain the study to the participating girls 
and their parents or guardian, obtain informed consent, 
administer the vaccines, record adverse events, and do 
follow-up procedures, including obtaining blood and 
cervical cell samples. Medical practitioners in the study 
clusters were trained to know how to manage or refer 
vaccinated girls who reported any adverse events after 
vaccination. Participants could contact a study clinician if 
they needed urgent medical attention using a 24-h 
telephone help line.
Each participant was visited every year by a health 
worker or nurse in her household to enquire about her 
general health and wellbeing. Details about marriage, 
medically signiﬁ cant events, pregnancy, antenatal and 
postnatal events, delivery, and migration were gathered 
and documented through the household visits, a network 
of social workers, medical-care providers, hospitals, and 
relatives. We obtained blood and cervical cell samples 
during designated periods.
Figure 1: Study proﬁ le
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Blood samples to determine immunogenicity were 
obtained by nurses during the vaccination session at a 
clinic or during household visits on day 1 and at 7, 12, 18, 
24, 36, 48, and 60 months from a cohort of a convenience 
sample of participants representing all included ages 
(10–18 years of age at study entry) of the vaccinated study 
population. Samples were treated with EDTA and 
analysed with Luminex (Austin, TX, USA) based multi-
plex serology8,9 to assess the concentration of binding 
antibodies against the major capsid protein L1 of 
HPV 16, 18, 6, and 11 as mean median ﬂ uorescence 
intensity (MFI; appendix). MFI values as a measure of 
antibody concentration quantiﬁ ed by use of HPV 
multiplex serology are directly comparable with optical 
densities measured with ELISA8 and MFI values for 
HPV 16 in natural and vaccine-induced HPV 16-speciﬁ c 
antibody responses are strongly correlated with end-
point titration titres in the neutralisation assay.9 
Seropositivity cutoﬀ s for seroconversion were calculated 
for each HPV type, based on the MFI values of serum 
samples obtained from the participants at baseline after 
allowing for 5% seropositivity in the total baseline 
samples. The immunogenicity measure was the 
geometric mean of MFI.8,9
Antibody avidity, which indicates the degree of antibody 
aﬃ  nity maturation, was measured with a modiﬁ ed 
version of the HPV-L1 genotype-speciﬁ c binding antibody 
assay described above (appendix).
Antibodies speciﬁ c for neutralising epitopes in HPV-L1 
protein were measured with a highly sensitive, automated, 
high-throughput pseudovirion-based neutra lisation assay 
(appendix).9 Bovine papillomavirus (BPV) pseudovirion 
assays were run as controls to verify that the test serum 
was not toxic to the cells; toxicity can mimic neutralisation.
Pelvic examination to obtain cervical cell samples was 
done in women 18 months after marriage or 6 months 
after delivery of their ﬁ rst child, whichever was earlier, 
and every year thereafter for 3 years. The HPV genotyping 
method involved HPV-type-speciﬁ c E7 PCR bead-based 
multiplex genotyping.10,11 The multiplex HPV-type-speciﬁ c 
E7 PCR uses HPV type-speciﬁ c primers targeting the E7 
region for the detection of 19 high-risk or probable high-
risk HPV types (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 
58, 59, 66, 68a, 68b, 70, 73, and 82), and two low-risk HPV 
types (6 and 11), with detection limits ranging from ten to 
1000 copies of the viral genome. The method was 
validated at the Rajiv Gandhi Centre for Biotechnology 
(RGCB; Thiruvananthapuram, India) under the super-
vision of scientists from IARC and the cervical cell 
samples were tested at RGCB. Women with two or more 
infections were only counted at the time of the ﬁ rst 
incident infection. We deﬁ ned incident infections that 
persisted for 12 months or longer without an HPV 
negative test (for the HPV type in question) between the 
positive tests as persistent infections.
Immunological assays and HPV testing were done at 
RGCB, where a dedicated laboratory was established with 
technology transfer and external quality assurance from 
the German Cancer Research Centre (DKFZ; Heidelberg, 
Germany) and the Infections and Cancer Biology Group at 
IARC (Lyon, France). Scientists from RGCB were trained 
at DKFZ, and the multiplex serology HPV-L1 antibody 
assays were done at RGCB by trained personnel, masked 
to the number of vaccine doses received by participants, 
under the technical supervision of experts from DKFZ.
Outcomes
The primary outcomes were immunogenicity outcomes: 
the HPV-L1 genotype-speciﬁ c binding antibody con-
centrations using geometric mean MFI, antibody avidity 
induced after vaccination using the geometric mean 
avidity index, and antibody concentrations speciﬁ c for 
neutralising epitopes in HPV-L1 using geometric mean 
neutralisation titres (GMTs); and infection outcomes: 
ﬁ rst incident and persistent infections of vaccine-
targeted HPV types accumulated during follow-up. 
Cervical cells were taken 6 months after delivery or 
18 months after marriage, whichever was earlier, and 
annually thereafter for 3 consecutive years.
For the HPV-L1 binding antibodies outcome, we 
compared the geometric mean MFIs at day 1 for all 
participants, at 7 months (1 month after the last dose), 
18 months, 36 months, and 48 months after the ﬁ rst dose 
of vaccination in the three-dose group versus the two-dose 
group, and at 18 months and 36 months after the ﬁ rst dose 
Three-dose 
group
Two-dose group Two-dose 
default group
One-dose 
default group
Number of participants 4348 4979 3452 4950
Age at recruitment (years)
10–14 2833 (65%) 3184 (64%) 2081 (60%) 2970 (60%)
15–18 1515 (35%) 1795 (36%) 1371 (40%) 1980 (40%)
Type of house
Thatched 399 (9%) 361 (7%) 329 (10%) 673 (14%)
Tiled 2844 (65%) 3299 (66%) 2657 (77%) 3412 (69%)
Concrete 1019 (23%) 1129 (23%) 463 (13%) 842 (17%)
Unknown 86 (2%) 190 (4%) 13 (<1%) 23 (<1%)
Household income (INR per month)
<2000 1451 (33%) 1454 (29%) 588 (17%) 957 (19%)
2000–4999 1808 (42%) 2103 (42%) 2291 (66%) 3186 (64%)
5000–9999 777 (18%) 1009 (20%) 421 (12%) 674 (14%)
≥10 000 308 (7%) 412 (8%) 149 (4%) 128 (3%)
Unknown 4 (<1%) 1 (<1%) 3 (<1%) 5 (<1%)
Participant’s education
None 46 (1%) 35 (<1%) 26 (<1%) 47 (<1%)
Primary 364 (8%) 443 (9%) 182 (5%) 629 (13%)
Middle 2018 (46%) 2383 (48%) 1174 (34%) 1773 (36%)
High 1464 (34%) 1556 (31%) 1442 (42%) 1746 (35%)
College 456 (10%) 561 (11%) 626 (18%) 755 (15%)
Unknown 0 1 (<1%) 2 (<1%) 0
Data are number or number (%). INR=Indian Rupees .
Table 1: Baseline characteristics
See Online for appendix
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of vaccination in the two-dose default and one-dose default 
groups versus the three-dose group. For the 12-month 
comparison, the MFIs in the one-dose default group were 
compared with those in the two-dose default group 
because other dose regimens were not measured at that 
timepoint. For the antibody avidity outcome, the geometric 
mean avidity indices were compared at 7 months for the 
two-dose and three-dose groups and at 18 months for all 
vaccination groups. For the neutralising antibody outcome, 
we compared the GMTs at 18 months for HPV 16, 18, and 
6 L1 in the two-dose, two-dose default, and one-dose default 
groups with those in the three-dose group.
The secondary outcomes were cross-protection against 
non-vaccine targeted high-risk HPV types: ﬁ rst incident 
and persistent non-targeted high-risk HPV infections 
accumulated during follow-up.
The study will be monitored and assessed over 20 years. 
Long-term outcomes, such as the frequency of cervical 
intraepithelial neoplasia grades 2 and 3 and invasive 
cancer, will be assessed by screening of participating 
women and using data from population-based cancer 
registries.
Statistical analysis
We aimed to recruit 20 000 girls from nine locations in 
India (7000 girls from Osmanabad, 3000 each from 
Dindigul, Pune, and Mumbai, 1000 each from Ahmedabad, 
Delhi, and Hyderabad, and 500 each from Gangtok in 
Sikkim, and Aizawl in Mizoram), with 10 000 girls living in 
100 clusters randomly allocated to the two-dose group and 
10 000 girls in 88 clusters to the three-dose group. To test 
for non-inferiority of antibody concentrations in diﬀ erent 
dose groups, we used log-transformed mean MFIs in 
linear regression models to obtain MFI ratios and their 
corresponding 95% CIs. In keeping with other HPV 
immunogenicity studies, non-inferiority of a vaccination 
group was concluded if the lower bound of the 95% CI for 
its MFI ratio was greater than 0·5.12–14 In a post-hoc power 
calculation, using the lowest limit of 95% CI with a sample 
size of 40 individuals per group, we had 90% power for 
non-inferiority testing between each of the observational 
groups and the three-dose group.
The antibody avidity index was calculated by dividing 
the MFI values of urea-treated samples by the MFI values 
of the untreated samples and multiplied by 100%. 
To compare the fewer than three-dose regimens with the 
three-dose regimen, log-transformed avidity index values 
were used in linear regression models to obtain avidity 
index ratios and their 95% CIs. Non-inferiority of the 
fewer than three-dose regimens to that of the three-dose 
regimen was concluded if the 95% CI lower bound of the 
avidity ratio index was greater than 0·5. Type-speciﬁ c 
seroprevalence for neutralisation titres is reported as a 
proportion. The neutralisation GMTs and their 95% CIs 
were compared by use of the log-transformed titre values 
in linear regression models. Non-inferiority of the GMT 
was concluded if the 95% CI lower bound of the 
neutralisation GMT ratio was greater than 0·5.
Figure 2: Mean MFI values for HPV types 16, 18, 6, and 11 L1 antibodies
Dashed lines show the threshold (cutoﬀ ) values for seroconversion. MFI=median ﬂ uorescence intensity. *MFI values for month 7 were used for the three-dose and 
two-dose vaccine groups, whereas MFI values for month 12 were used for the two-dose default and one-dose default groups. 
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Because of the initial cluster randomisation design, 
responses within the clusters might be more correlated 
than those between the clusters. For this reason, all 
regression analyses were adjusted for the cluster design 
by specifying the option in the regression models that 
allows the variance-covariance estimator to include the 
clustering eﬀ ect.
HPV infection outcomes are reported as frequencies of 
the detection of ﬁ rst incident infection and persistent 
infections of vaccine-targeted and non-targeted high-risk 
HPV infections accumulated during the follow-up.
For both the primary and secondary outcomes, analysis 
was done per the actual number of vaccine doses a 
participant received. The statistical analyses were done 
with Stata (version 13.1).
This study is registered with ISRCTN, number 
ISRCTN98283094, and with ClinicalTrials.gov, number 
NCT00923702.
Role of the funding source
The funder had no role in the design, conduct, 
monitoring, and assessment of the study, analysis of 
data, or writing of the report. Other than the donation of 
the vaccines, Merck did not have any role in design, 
protocol development, study conduct, monitoring, and 
assessment, analysis of data, or writing of the report. 
AM, BMN, EL, EZ, GJ, KJ, MP, MM, MT, NB, POE, 
PRP, PS, RM, MRP, RS, SS, SJ, SGM, SSS,TG, URRP, 
and YV had access to the raw data. The corresponding 
author had full access to all the data in the study and all 
the authors had ﬁ nal approval for the decision to 
submit.
Results
Vaccination of eligible girls was initiated on Sept 1, 2009, 
and continued until April 8, 2010. Of the 21 258 eligible 
girls identiﬁ ed for recruitment in the 188 clusters, 
17 729 (83%) from 178 clusters were vaccinated at least 
once: 4348 (25%) girls received three doses on days 1, 60, 
and 180 or later (three-dose group); 4979 (28%) received 
two doses on days 1 and 180 or later (two-dose group); 
3452 (19%) received two doses on days 1 and 60 by default 
(two-dose default group); and 4950 (28%) received one dose 
by default (one-dose default group; ﬁ gure 1; appendix). The 
baseline characteristics of participants in the four groups 
show more or less similar age distribution, whereas we 
noted some diﬀ erences in average monthly household 
income and education (table 1). Local and systemic 
reactions within 15 days of administering 34 856 vaccine 
doses in the study included injection-site pain (number of 
reactions; n=1092), low-grade fever (n=293), injection-
site swelling (n=124), dizziness (n=64), headache 
(n=49), nausea (n=30), skin rash (n=15), diarrhoea (n=13), 
abdominal cramps (n=13), and fainting attacks (n=10). 
No serious adverse events were attributable to the vaccine. 
Median follow-up was 4·7 years (IQR 4·2–5·1).
Results of the HPV-L1 binding antibody analyses are in 
the appendix. The MFI threshold values for 
seroconversion for HPV 16, 18, 6, and 11 L1 were 100, 41, 
240, and 48, respectively. Analysis of 625 plasma samples 
(308 in the three-dose group and 317 in the two-dose 
group) obtained at month 7 for peak HPV-L1 binding 
antibody concentrations indicated that all girls in both 
groups had seroconverted and almost all girls in the two-
dose group had MFIs equal to or higher than the lowest 
MFI in the three-dose group for all four vaccine-targeted 
HPV types (appendix). The peak antibody concentrations 
at 7 months for vaccine-targeted HPV types in the two-
dose cohort were non-inferior to the MFIs in the three-
dose group (appendix). MFI ratios for the two-dose versus 
three-dose group were 1·12 (95% CI 1·02–1·23) for HPV 
16 L1, 1·04 (0·92–1·19) for HPV 18 L1, 1·04 (0·97–1·13) 
for HPV 6 L1, and 1·12 (1·06–1·19) for HPV 11 L1.
The HPV-L1 binding antibody concentrations for the 
vaccine-targeted HPV types were similar for the three-
dose and two-dose groups over 48 months (ﬁ gure 2; 
appendix). The antibody concentrations in the two-dose 
vaccine group had similar decay kinetics and were non-
inferior to those in the three-dose group at 7 months, 
18 months, 36 months, and 48 months, over the 48-month 
period (appendix). At least 124 (98%) of 127 girls in the 
two-dose group had antibody concentrations equal to or 
greater than the lowest antibody MFI in the three-dose 
group at 48 months (appendix). 
The HPV-L1 binding antibody concentrations for the 
vaccine-targeted HPV types in the two-dose default and 
one-dose default groups were inferior to the concen-
trations in the three-dose group at 18 months and 
36 months. At month 18, the number of samples analysed 
was 313 in the three-dose group, 449 in the two-dose 
Figure 3: Box plots of the avidity index of MFI for HPV types 16 (A), 18 (B), 6 (C), and 11 (D) L1 antibodies at 
7 months and 18 months after the ﬁ rst dose 
MFI=median ﬂ uorescence intensity. 
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default group, and 476 in the one-dose default group. 
At month 36, the number of samples analysed was 271 in 
the three-dose group, 513 in the two-dose default group, 
and 510 in the one-dose default group (appendix). At 
month 18, MFI ratios of the two-dose default group 
compared with the three-dose group were 0·33 (95% CI 
0·29–0·38) for HPV 16 L1, 0·51 (0·43–0·59) for HPV 18 
L1, 0·48 (0·42–0·55) for HPV 6 L1, and 0·40 (0·35–0·45) 
for HPV 11 L1. For the one-dose default group compared 
with the three-dose group, month 18 MFI ratios were 
0·09 (0·08–0·11) for HPV 16 L1, 0·12 (0·10–0·14) for 
HPV 18 L1, 0·17 (0·15–0·20) for HPV 6 L1, and 0·12 
(0·11–0·14) for HPV 11 L1 (ﬁ gure 2; appendix). For the 
two-dose default group versus the three-dose group, 
month 36 MFI ratios were 0·62 (0·54–0·71) for HPV 16 
L1, 0·55 (0·47–0·64) for HPV 18 L1, 0·46 (0·40–0·53) for 
HPV 6 L1, and 0·39 (0·34–0·45) for HPV 11 L1. For the 
one-dose default group compared with the three-dose 
group, month 36 MFI ratios were 0·33 (0·28–0·37) for 
HPV 16 L1, 0·25 (0·21–0·29) for HPV 18 L1, 0·21 
(0·18–0·24) for HPV 6 L1, and 0·18 (0·16–0·21) for HPV 
11 L1 (ﬁ gure 2; appendix). At 36 months, 511 (>99%) of 
513 girls in the two-dose default group and 462 (91%) of 
510 in the one-dose default group had antibody 
concentrations equal to or higher than the lowest MFI 
value in the three-dose group (appendix). There was no 
correlation between age and antibody titres in the one-
dose default group (correlation coeﬃ  cient=0∙067).
The values for geometric mean avidity index for HPV 
types 16, 18, 6, and 11 after the two-dose schedule at 
7 months and after the two-dose, two-dose default, and 
one-dose default schedules at 18 months, were non-
inferior to the value after the three-dose regimen. 
For example, the avidity index ratio of the one-dose default 
group compared with the three-dose group for HPV 16 L1 
was 1·10 (95% CI 1·01–1·19; ﬁ gure 3; appendix).
The GMTs of neutralising antibodies to HPV types 16 
and 6 at 18 months after the ﬁ rst dose in the two-dose 
group were non-inferior to the GMTs in the three-dose 
group, but were inferior for HPV 18. The GMT ratio of 
HPV 16 L1 neutralisation titres was 1·00 (95% CI 
0·69–1·45) for the two-dose group compared with the 
three-dose group, whereas for HPV 18 L1 neutralisation 
titres, it was 0·42 (0·27–0·65) for the two-dose group 
compared with the three-dose group (ﬁ gure 4; appendix). 
The GMT after the two-dose default and one-dose default 
schedules for HPV types 16, 18, and 6 were inferior to the 
GMT of the three-dose group (ﬁ gure 4; appendix). The 
GMT ratio of HPV 16 L1 neutralisation titres was 0·23 
(0·16–0·34) for the two-dose default group compared 
with the three-dose group.
The median time between ﬁ rst vaccination and ﬁ rst 
cervical sample collection from 2649 participants was 
3∙9 years (IQR 3∙0–4∙7). The medians were 4·1 years 
(IQR 3·3–4·8) for the three-dose group, 4·3 years 
(3·3–4·8) for the two-dose group, 3·7 years (2·9–4·6) 
for the two-dose default group, and 3·7 years (2·9–4·5) 
for the one-dose default group. The incidence of vaccine-
targeted and non-vaccine-targeted HPV infections is 
shown in table 2. In 838 women for whom two or more 
samples were available for analysis, there were no 
persistent HPV 16 and 18 infections in any of the four 
study groups at a median follow-up of 4·7 years 
(IQR 4·2–5·1; table 2). Higher frequencies of persistent 
vaccine non-targeted HPV infections were noted in the 
four study groups as compared with vaccine-targeted 
HPV infections.
Discussion
Our ﬁ ndings suggest that two doses of quadrivalent HPV 
vaccine, administered with an interval of 180 days or more 
between doses, are immunologically non-inferior to the 
three-dose schedule and aﬀ ord protection against incident 
and persistent HPV 16, 18, 6, and 11 infections that is 
similar to that aﬀ orded by three doses. Low frequencies of 
premarital sexual activity, smoking, drinking, oral 
contraceptive use, and HPV infection have been reported 
for pre-adolescent and adolescent, unmarried girls in 
India.15–19 The frequency of any HPV infection in young 
married women in India ranges from 7% to 19%, and the 
Figure 4: Box plots of neutralisation titres of HPV types 16 (A), 18 (B), and 6 (C) L1 antibodies at 18 months after the ﬁ rst dose 
Samples without neutralising activity were not included in the GMT analyses. GMT=geometric mean neutralisation titre. 
2
4
6
8
10
12
N
at
ur
al
 lo
g 
GM
T 
ne
ut
ra
lis
at
io
n 
tit
re
s
A HPV 16 L1 B HPV 18 L1 C HPV 6 L1
Th
ree
 do
ses
Tw
o d
os
es
Tw
o d
os
es,
 de
fau
lt
On
e d
os
e, d
efa
ult
Th
ree
 do
ses
Tw
o d
os
es
Tw
o d
os
es,
 de
fau
lt
On
e d
os
e, d
efa
ult
Th
ree
 do
ses
Tw
o d
os
es
Tw
o d
os
es,
 de
fau
lt
On
e d
os
e, d
efa
ult
Doses received Doses received Doses received
Articles
74 www.thelancet.com/oncology   Vol 17   January 2016
frequency of HPV types 16 and 18 infections range from 
3% to 9%.20–23 In this context, our initial results provide 
new evidence that one and two doses of quadrivalent 
vaccine prevent incident and persistent cervical infections 
with HPV types 16, 18, 6, and 11, similar to the protection 
aﬀ orded after a three-dose schedule during a median 
follow-up of 4·7 years (IQR 4·2–5·1).
To our knowledge, our study is the ﬁ rst in which 
immunogenicity and vaccine-targeted HPV infection 
frequencies are reported after one dose of quadrivalent 
vaccine. Although the antibody concentrations after one 
dose were lower than those in the two-dose and three-dose 
groups, the titres were stable and the mean avidity index 
after one dose was non-inferior to that after three doses. 
Vaccine-induced HPV L1 binding antibody concentrations 
measured with multiplex serology correlated well with the 
concentrations of serum HPV-neutralising activity after 
the diﬀ erent dose regimens. Additionally, the frequencies 
of incident and persistent vaccine-targeted HPV infections 
after one dose were similar to those after three and two 
doses. One-dose vaccination also induced detectable titres 
of neutralising antibodies to all four vaccine-targeted HPV 
HPV incidence HPV infection status
Women 
assessed
Women 
with 
incident 
infections
Incidence (95% CI) Remained 
negative
Negative 
turned 
positive*
Cleared Persistent
HPV 16 or 18 infections
Three doses of vaccine 536 2 0·4% (0·0–1·3) 171 (31·9%) 1 (0·2%) 0 0
Two doses of vaccine 526 4 0·8% (0·2–1·9) 128 (24·3%) 1 (0·2%) 0 0
Two doses of vaccine by default 717 9 1·3% (0·6–2·4) 257 (35·8%) 2 (0·3%) 1 (0·3%) 0
One dose of vaccine by default 870 10 1·1% (0·6–2·1) 268 (30·8%) 8 (0·9%) 1 (0·1%) 0
HPV 16 infection
Three doses of vaccine 536 2 0·4% (0·0–1·3) 171 (31·9%) 1 (0·2%) 0 0
Two doses of vaccine 526 3 0·6% (0·1–1·7) 128 (24·3%) 1 (0·2%) 0 0
Two doses of vaccine by default 717 8 1·1% (0·5–2·2) 257 (35·8%) 2 (0·3%) 1 (0·1%) 0
One dose of vaccine by default 870 9 1·0% (0·5–2·0) 268 (30·8%) 8 (0·9%) 1 (0·1%) 0
HPV 18 infection
Three doses of vaccine 536 0 0 172 (32·1%) 0 0 0
Two doses of vaccine 526 1 0·2% (0·0–1·1) 129 (24·5%) 0 0 0
Two doses of vaccine by default 717 1 0·1% (0·0–0·8) 260 (36·3%) 0 0 0
One dose of vaccine by default 870 1 0·1% (0·0–0·6) 277 (31·8%) 0 0 0
HPV 6 or 11 infections
Three doses of vaccine 536 1 0·2% (0·0–1·0) 171 (31·9%) 0 1 (0·2%) 0
Two doses of vaccine 526 1 0·2% (0·0–1·1) 129 (24·5%) 0 0 0
Two doses of vaccine by default 717 5 0·7% (0·2–1·6) 256 (35·7%) 1 (0·1%) 2 (0·3%) 1 (0·1%)
One dose of vaccine by default 870 4 0·5% (0·1–1·2) 275 (31·6%) 0 2 (0·2%) 0
HPV 16 or 18 or 6 or 11 infections
Three doses of vaccine 536 3 0·6% (0·1–1·6) 170 (31·7%) 1 (0·2%) 1 (0·2%) 0
Two doses of vaccine 526 5 1·0% (0·3–2·2) 128 (24·3%) 1 (0·2%) 0 0
Two doses of vaccine by default 717 14 2·0% (1·1–3·3) 253 (35·3%) 3 (0·4%) 3 (0·4%) 1 (0·1%)
One dose of vaccine by default 870 14 1·6% (0·9–2·7) 266 (31%) 8 (0·9%) 3 (0·3%) 0
Non-vaccine-targeted HPV 31 or 33 or 45 infections
Three doses of vaccine 536 32 6·0% (4·1–8·3) 155 (29%) 8 (0·3%) 9 (1·7%) 0
Two doses of vaccine 526 26 4·9% (3·3–7·2) 123 (23·4%) 1 (0·2%) 5 (1·0%) 0
Two doses of vaccine by default 717 33 4·6% (3·2–6·4) 239 (33·3%) 8 (1·1%) 12 (1·7%) 1 (0·3%)
One dose of vaccine by default 870 77 8·9% (7·0–10·9) 230 (26·4%) 8 (0·9%) 35 (4·0%) 4 (0·5%)
Non-vaccine-targeted HPV infections excluding 31, 33, and 45
Three doses of vaccine 536 74 13·8% (11·0–17·0) 139 (26·9%) 12 (2·2%) 17 (3·2%) 4 (0·7%)
Two doses of vaccine 526 48 9·1% (6·8–11·9) 113 (21·5%) 8 (1·5%) 7 (1·3%) 1 (0·9%)
Two doses of vaccine by default 717 68 9·5% (7·4–11·9) 223 (31·1%) 11 (1·5%) 22 (3·1%) 4 (0·6%)
One dose of vaccine by default 870 118 13·6% (11·4–16·0) 222 (25·5%) 19 (2·2%) 32 (3·7%) 4 (0·5%)
Data are number (%), unless otherwise indicated. HPV incidence assessed in women with at least one sample tested. HPV infection status assessed in women with at least 
two samples tested at 12 months apart. *Incident HPV infections with no subsequent sample to assess persistence.
 Table 2: Incident HPV infection and HPV infection status 
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types in most of the participants that were assessed, but at 
a much lower concentration. There is no known minimum 
threshold concentration of antibodies that is protective; 
seroconversion is an arbitrary cutoﬀ  and does not rep-
resent the minimum threshold for protection.1,24
Our immunogenicity ﬁ ndings after three and two doses 
of vaccine are consistent with the results from a Canadian 
randomised trial25 in which 261 girls aged 9–13 years were 
allocated to vaccine with three doses of quadrivalent 
vaccine at day 1, 2 months, and 6 months; 259 girls also 
aged 9–13 years were allocated to vaccine with two doses at 
day 1 and 6 months; and 310 women aged 16–26 years 
were allocated to vaccine with three doses also at day 1, 
2 months, and 6 months. The antibody concentrations for 
all four vaccine-targeted HPV types in the girls aged 
9–13 years given two doses were non-inferior to those in 
women aged 16–26 years who received three doses during 
a 36-month period. Similarly, antibody concentrations 
after two doses of bivalent vaccine administered on days 1 
and 180 were non-inferior to the concentrations after the 
three-dose schedule in several studies.26–28
In a non-randomised comparison of the bivalent HPV 
vaccine in the context of the Costa Rica Vaccine and 
PATRICIA trials, one and two doses were as protective as 
three doses in preventing persistent HPV 16 or 18 
infections.29,30 The non-signiﬁ cant diﬀ erences in the 
frequencies of incident and persistent infections with 
HPV types 16, 18, 6, and 11 after the four diﬀ erent dose 
schedules shown in our study is new evidence for the 
protective eﬃ  cacy of two doses and one dose of 
quadrivalent vaccine in the short term. The frequencies of 
HPV 16 and 18 infections in our vaccinated study groups 
are substantially lower than the 3–9% frequency of such 
infections reported in unvaccinated young women in 
India.20–23 Distinguishing between a positive HPV DNA 
result due to an incident infection and that due to a recent 
exposure is not possible. Our results suggest that the low 
vaccine-induced antibody concentrations after one dose 
aﬀ ord similar protection against vaccine-targeted HPV 
infections as the high antibody concentrations from two 
or three doses during a median follow-up of 4·7 years 
(IQR 4·2–5·1). The similar frequency of incident non-
vaccine HPV types in each dose group (table 2) implies 
that HPV exposure was similar across the diﬀ erent 
groups and participants’ sexual behaviours were not 
related to the number of doses received. A follow-up of 
these women is planned over 20 years to assess the 
eﬃ  cacy endpoints for the incidence of cervical intra-
epithelial neoplasia grades 2 and 3 and invasive cervical 
cancer caused by vaccine-targeted and non-targeted HPV 
types in the diﬀ erent dose groups by screening of 
participating women and using data from population-
based cancer registries. We have also recruited and are 
following up an age-matched and residence-matched 
cohort of unvaccinated women (n=1540).
The protection aﬀ orded by virus-like particle vaccines 
is believed to be mediated by neutralising antibodies 
produced by plasma cells,31,32 most of which have short 
lifespans, leading to declines in peak antibody 
concentrations within a few months. By contrast, some 
antibody-secreting cells become long-lived plasma cells. 
Concentrations of antibodies measured 12–18 months 
after the last dose of a virus-like particle vaccine generally 
represent the activity of long-lived plasma cells and are 
the best predictors of antibody persistence.
The patterns of antibody responses after one dose of 
vaccine in our study and in the Costa Rica and PATRICIA 
trials27,30 seem to be similar to the pattern after a live 
attenuated vaccine, which usually aﬀ ords long-lasting 
protection. The stable antibody response after one dose of 
the HPV L1 vaccine might be due to the structure of the 
HPV-like particles and the antigens it displays to the 
immune system might eliminate the need for doses after 
the priming dose.27,33,34 Notably, in a cohort study35 in which 
girls aged 10–24 years and women received three doses 
(n=98 252), two doses by default (n=112 555), and one dose 
by default (n=119 046) of the quadrivalent vaccine, the 
incidence rate ratios for the occurrence of condylomas 
were 0·18, 0·29, and 0·31, respectively, implying that one 
dose and two doses with a short interval were associated 
with signiﬁ cant reduction in condyloma risk compared 
with 926 119 unvaccinated women.
Due to the disruption of recruitment and randomisation 
because of the suspension of vaccination midway in our 
planned two-arm randomised trial, our study has essentially 
become an observational cohort study of participants in 
four dose groups with similar socio demographic charac-
teristics. Vaccination was suspended in our study in 
response to instructions from the Indian Council of 
Medical Research in the context of all HPV vaccination 
studies in India pending an enquiry into the causes of 
death of ﬁ ve girls (subsequently proven unrelated to HPV 
vaccination) recruited for an HPV vaccination demon-
stration project in the states of Andhra Pradesh and 
Gujarat. Major limitations include the non-randomised 
comparison of the vaccination dose groups, an absence of 
memory B-cell response data, limitations in interpreting 
early results for girls given incomplete dose schedules, and 
biases that might have been introduced after vaccination 
interruption and loss of randomisation. Despite these 
limitations, our study of HPV vaccination is representative 
of generalisable real-world conditions: it had varying dose 
schedules and a broad age range of participants in addition 
to the diﬃ  culties and challenges inherent in running HPV 
vaccination studies in low-income and middle-income 
countries. Moreover, the inclusion of sexually naive girls 
aged 10–18 years (the primary and secondary target age 
groups for vaccination), the possibility of long-term follow-
up, and the technology transfer that allowed validated and 
quality assured execution of antibody assays and HPV 
genotyping and the resultant independence in assessing 
outcomes without having to rely on pharmaceutical 
industry laboratories or laboratories abroad are important 
strengths of our study.
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participated in the monitoring, supervision, acquisition, and 
interpretation of the data, and the provision of clinical services at their 
respective study sites. 
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preted with caution and suggest that future trials of HPV 
vaccines should include a single dose arm. Further long-
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Our ﬁ ndings support the WHO recommendation to 
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